普伐他汀与非诺贝特治疗高脂血症的疗效

Efficacy of Combination Therapy with Pravastatin and Fenofibrate for Mixed Hyperlipidemia

目的:探讨普伐他汀和非诺贝特联合应用治疗混合性高脂血症的疗效及安全性。方法:102例混合性高脂血症患者,随机分为普伐他汀组(10mg/d,n=51)和联合治疗组(普伐他汀10mg/d+非诺贝特200mg/d,n=51),共治疗6个月。观察治疗前后主要血脂参数的变化、总有效率、与治疗安全性有关的指标以及不良反应。结果:联合治疗组血脂参数的变化率最显著,血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)分别下降30%、36%和55%,而血清高密度脂蛋白胆固醇(HDL-C)升高24%,联合治疗组TG和HDL-C的总有效率明显高于普伐他汀组(P<0.01)。结论:普伐他汀与非诺贝特联合治疗混合性高脂血症患者能更全面调节血脂异常,疗效优于单用普伐他汀治疗。

Objective： To evaluate the efficacy and safety of combination therapy with pravastatin and fenofibrate in patients with mixed hyperlipidemia. Method ： A total of 102 patients with mixed hyperlipidemia, were randomly assigned to receive pravastatin 10 mg （ n = 51 ） or a combination of pravastatin 10 mg fenofibrate 200 mg（ n = 51 ） for 6 months. Lipid profiles, physical and laboratory investigations for efficacy, safety and adverse effees were assessed. Result： combination treatment were more effective in normalizing lipid profile than any monotherapy. Serum TC, LDL-C, and Tg were reduced by 30% ,36%, and 55% respectively, whilst HDL-C was significantly increased by 24%. A total effective rate of combination treatment in TG and HDL-C was superior to pravastatin. Conclusion： combination therapy with fenofibrate and pravastatin is more effective than monotherapy in patients with mixed hyperlipidemia.